Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart

Ambarish Pandey; Javed Butler

doi:10.1002/ejhf.2313

Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	1552-1554
Number of pages	3
Journal	European Journal of Heart Failure
Volume	23
Issue number	9
DOIs	https://doi.org/10.1002/ejhf.2313
State	Published - Sep 2021

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/ejhf.2313

Cite this

@article{15ba0f9e20a14665adefe636288f8c9e,

title = "Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart",

author = "Ambarish Pandey and Javed Butler",

note = "Funding Information: A.P. has served on the advisory board of Roche Diagnostics, has received non‐financial support from Pfizer and Merck, and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute of Aging GEMSSTAR Grant (1R03AG067960‐01), and Applied Therapeutics. J.B. is a consultant to Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol‐Myers Squib, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, SC Pharma, V‐Wave Limited, and Vifor. Conflict of interest:",

year = "2021",

month = sep,

doi = "10.1002/ejhf.2313",

language = "English (US)",

volume = "23",

pages = "1552--1554",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart

AU - Pandey, Ambarish

AU - Butler, Javed

N1 - Funding Information: A.P. has served on the advisory board of Roche Diagnostics, has received non‐financial support from Pfizer and Merck, and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute of Aging GEMSSTAR Grant (1R03AG067960‐01), and Applied Therapeutics. J.B. is a consultant to Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol‐Myers Squib, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, SC Pharma, V‐Wave Limited, and Vifor. Conflict of interest:

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85111819572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111819572&partnerID=8YFLogxK

U2 - 10.1002/ejhf.2313

DO - 10.1002/ejhf.2313

M3 - Editorial

C2 - 34296493

AN - SCOPUS:85111819572

SN - 1388-9842

VL - 23

SP - 1552

EP - 1554

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 9

ER -

Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this